best peptides FAQ

Cerebrolysin has the strongest evidence base for vascular depression and post-stroke MDD. A meta-analysis of 11 RCTs (n=842) demonstrated 35–50% symptom reduction with 10–30 mL IV administration over 10–21 days. Vascular depression. Characterized by late-life onset, executive dysfunction, psychomotor slowing, and MRI evidence of white matter hyperintensities. Responds poorly to SSRIs because the underlying pathology is structural (ischemic lesions, oligodendrocyte death) rather than purely neurochemical. Cerebrolysin's neurotrophic factor content promotes angiogenesis and remyelination, addressing the structural deficit directly. This makes it uniquely suited to elderly populations with cerebrovascular disease, a demographic where SSRI efficacy drops significantly.

Stack peptides sequentially rather than simultaneously when initiating research protocols. Begin with a single growth hormone secretagogue (Ipamorelin or MK-677) for 4–6 weeks to establish baseline response and tolerance, then layer in CJC-1295 or IGF-1 LR3 if muscle mass gains plateau. Combining three or more anabolic peptides from the start increases the difficulty of attributing side effects (edema, joint pain, glucose dysregulation) to specific compounds. Preclinical models and early-phase human trials universally use monotherapy before advancing to combination protocols. Researchers should follow the same staged approach.

Peptides offer mechanistically distinct alternatives. If SSRIs caused sexual dysfunction, weight gain, or emotional blunting. Outcomes affecting 40–60% of users. Selank or Semax operate through entirely different pathways (GABAergic modulation and neurotrophic support vs serotonin reuptake inhibition). If benzodiazepines produced dependency or cognitive fog, Selank provides anxiolysis without GABA-A receptor desensitization. The critical difference: peptides don't require 4–8 week titration periods or produce discontinuation syndromes. Effects manifest within days to weeks depending on compound, and cessation doesn't trigger rebound anxiety or withdrawal. We've observed researchers transitioning subjects from failed SSRI trials to peptide protocols with remarkable compliance improvements. Primarily because side effect profiles are dramatically more favorable.

Distinguish between acute and chronic inflammatory states. Acute inflammation (injury, flare-up) benefits from peptides that accelerate inflammation resolution like TB-500, which helps transition from pro-inflammatory to tissue repair phases. Chronic inflammatory conditions (rheumatoid arthritis, psoriatic arthritis) respond better to immune-modulating peptides like KPV or Thymosin Alpha-1, which recalibrate T-cell populations and reduce NF-κB-driven inflammatory gene expression. Mechanical osteoarthritis doesn't respond well to anti-inflammatory peptides alone. The pathology is tissue degradation, not immune dysfunction.

Relapse within 6–12 months post-treatment suggests either residual persister spirochetes or established immune dysfunction maintaining symptoms independently. LL-37 2–5mg daily for 4–6 weeks addresses potential persister populations through membrane disruption mechanisms—unlike antibiotics, LL-37 kills metabolically dormant bacteria. If symptoms persist beyond LL-37 treatment, shift focus to immune restoration with Thymalin or Thymosin Alpha-1—at that point, immune dysregulation is the driver, not residual infection.

Administer antimicrobial peptides like LL-37 or KPV first. Regenerative peptides cannot engage their mechanisms in the presence of active infection. Bacterial endotoxins suppress fibroblast activity and VEGF expression. LL-37 disrupts bacterial membranes through electrostatic interaction, effective against both Gram-positive and Gram-negative organisms. Apply topically at 10–50 mcg/mL once biofilm is mechanically debrided. Wait 48–72 hours for microbial load reduction (confirmed via wound culture or clinical assessment) before introducing BPC-157 or TB-500. Combining antimicrobial and angiogenic peptides simultaneously often results in suboptimal outcomes for both.

Verify peptide purity and reconstitution accuracy first. Amino acid sequencing errors or improper storage conditions are the most common causes of null results. BPC-157's mechanism depends on VEGF receptor activation, which requires intact peptide structure. If sequencing and storage are confirmed correct, consider dose insufficiency (animal studies use 10 mcg/kg or higher), administration timing relative to inflammatory insult, or model-specific factors like baseline VEGF expression levels.

Semax or Cerebrolysin become primary candidates when stress manifests as brain fog, impaired working memory, or difficulty concentrating. Semax's BDNF upregulation directly counters stress-induced hippocampal atrophy. The mechanism behind memory consolidation failures many chronic stress sufferers experience. Start with Semax amidate 300–600mcg intranasal daily for 28 days. If cognitive symptoms include executive function impairment (decision-making, task-switching), consider Dihexa. A research peptide demonstrating potent synaptogenic effects through hepatocyte growth factor (HGF) pathway activation. Animal models show Dihexa enhances dendritic spine density by 40–50% within 14 days at 5mg/kg oral dosing.

Nausea occurs in approximately 30–40% of men during initial PT-141 or melanotan II administration due to melanocortin receptor activation in the brainstem area postrema, which regulates nausea and emesis. Dose reduction (starting at 0.5mg for melanotan II or 1mg for PT-141) and slow titration over 2–3 administrations typically resolves symptoms as central melanocortin receptors downregulate. Flushing results from peripheral vasodilation and usually resolves within 60–90 minutes. Pretreatment with an H2-receptor antagonist (famotidine 20mg) may reduce flushing intensity without impairing erectile response.

Peptides are fragile molecules. Improper storage (temperatures above 8°C for reconstituted solutions) or contaminated bacteriostatic water causes protein denaturation. The peptide loses its three-dimensional structure and becomes biologically inactive. There's no home test for potency. Visual inspection only catches gross contamination (cloudiness, particulates), not loss of bioactivity. Purchasing from suppliers that provide third-party purity verification and proper storage guidance is non-negotiable. At Real Peptides, every batch undergoes amino acid sequencing and HPLC analysis to verify exact peptide structure and purity before shipping. This isn't standard across the industry.

Kisspeptin-10 stimulates endogenous LH and FSH release without suppressing the hypothalamic-pituitary axis, meaning it does not cause testicular atrophy or spermatogenic shutdown the way exogenous testosterone does. This makes kisspeptin-10 the only hormonal intervention that can restore testosterone levels while preserving or even enhancing fertility. Exogenous testosterone replacement would suppress FSH and halt spermatogenesis within 8–12 weeks, making it unsuitable for men planning conception.

Use BPC-157 or TB-500 for acute injuries. Ligament tears, tendon strains, post-surgical repair. Both peptides accelerate the initial phases of tissue healing by increasing cell migration and collagen deposition at injury sites. For chronic osteoarthritis where cartilage has thinned over years, growth hormone secretagogues (Ipamorelin, CJC-1295) provide a permissive environment for cartilage maintenance by sustaining IGF-1 elevation. Acute injuries show response within 2–4 weeks; chronic cartilage support requires 8–16 weeks minimum because chondrocyte metabolic rate is exceptionally slow.

Combination protocols may be appropriate. Kisspeptin-10 to restore testosterone production and PT-141 to address central arousal deficits. The two peptides act on distinct pathways and do not compete or interfere mechanistically. Clinical trials have not formally evaluated this combination, but the pharmacological rationale is sound: normalize hormonal support first (kisspeptin-10 administered daily for 2–4 weeks to restore baseline testosterone), then address residual arousal or performance anxiety with PT-141 as needed before sexual activity.

AOD-9604 and MOTS-c are ideal because neither affects insulin or glucose metabolism. AOD-9604 acts exclusively on adipose tissue via beta-3 adrenergic receptors, and MOTS-c actually improves insulin sensitivity by activating AMPK and increasing glucose uptake in skeletal muscle. Avoid IGF-1 LR3 in this context. It can cause hypoglycemia in insulin-resistant individuals due to direct insulin-like effects on glucose uptake. GH secretagogues (CJC-1295, Ipamorelin, MK-677) are generally safe but should be monitored. GH is mildly insulin-antagonistic, meaning it can raise fasting glucose slightly in predisposed individuals.

Discard it. Peptides are proteins. Temperature excursions above 8°C cause irreversible denaturation that neither visual inspection nor home potency testing can detect. Lyophilized peptides tolerate short-term ambient temperatures (up to 25°C for 48 hours), but reconstituted solutions must remain refrigerated. If a vial was left at room temperature for more than 4 hours, assume complete loss of activity. The financial cost of replacing a compromised vial is lower than the research cost of using inactive peptide and drawing false conclusions about efficacy.

Increase dietary protein to 2.0–2.2 g/kg body weight daily and verify leucine content reaches 2.5–3.0 g per meal. Growth hormone and IGF-1 elevation create the hormonal environment for muscle protein synthesis, but without adequate amino acid substrate and resistance training stimulus, anabolic signaling goes unused. Research published in the Journal of Nutrition found that older adults require 40% higher per-meal protein doses than younger adults to achieve equivalent mTOR activation. GH secretagogues amplify this requirement rather than eliminate it.

Elevated C-reactive protein, ESR, or pro-inflammatory cytokines (TNF-alpha, IL-6) six months post-antibiotic suggest immune dysregulation, not active infection. KPV 500–1000mcg daily addresses NF-κB-driven inflammation, particularly if gut symptoms (bloating, irregular bowel movements) persist—gut barrier dysfunction perpetuates systemic inflammation through endotoxin translocation. Combine with VIP 100–200mcg intranasally twice daily if neurological symptoms (brain fog, memory issues, mood changes) dominate the clinical picture—VIP crosses the blood-brain barrier and reduces neuroinflammation through macrophage M2 polarization.

Increase the lipolytic stimulus by adding a metabolic modulator like AOD-9604 or MOTS-c. GH secretagogues elevate GH and IGF-1, but if you're in a caloric surplus or consuming high insulin-spiking meals around dosing windows, the anabolic signal dominates and fat oxidation is suppressed. GH stimulates lipolysis only in a low-insulin state. If insulin is elevated, hormone-sensitive lipase (the enzyme that breaks down triglycerides) is inhibited regardless of GH levels. The solution is either tighter dietary control (fasted cardio post-injection, carbohydrate timing away from GH pulses) or the addition of a peptide that bypasses insulin signaling entirely, like AOD-9604.

Intranasal bioavailability depends on mucosal health, sinus inflammation, and administration technique. Subcutaneous injection bypasses first-pass metabolism and mucosal barriers entirely, producing more consistent plasma concentrations. Particularly relevant for peptides like Semax and Selank. For researchers prioritising reproducibility, subcutaneous administration at 200–400 mcg per day produces tighter dose-response curves than intranasal protocols, though convenience favors the latter in human studies.

Thymosin Alpha-1 acts systemically on T-cell populations rather than directly on gut epithelium. Its effects on intestinal inflammation are mediated through immune modulation in gut-associated lymphoid tissue (GALT). Measurable changes may appear in systemic cytokine profiles or immune cell populations before histological improvements in mucosal tissue. If the study design expects direct epithelial repair, a compound targeting tight junctions or mucosal angiogenesis like BPC-157 may be more appropriate.